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Abstract
The present invention relates to the isolation, purification, sequencing, and functional characterization of the
class I diterpene synthase sequence OsKSLl 1. Transcriptional control of OsKSLll provides a means of
regulating production of stemodene. Further, since OsKSLll is highly homologous to OsKSL8, identification
of the sequence of OsKSLll will facilitate identification of underlying enzymatic determinants that affect
product outcomes With these enzymes.
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The present invention relates to the isolation, puri?cation, 
sequencing, and functional characterization of the class I 
diterpene synthase sequence OsKSLl 1. Transcriptional con 
trol of OsKSLll provides a means of regulating production 
of stemodene. Further, since OsKSLll is highly homologous 
to OsKSL8, identi?cation of the sequence of OsKSLll Will 
facilitate identi?cation of underlying enzymatic determinants 
that affect product outcomes With these enzymes. 
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IDENTIFICATION OF SYN-STEMODENE 
SYNTHASE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to provisional application 
Ser. No. 60/827, 93 5 ?led Oct. 3, 2006, herein incorporated by 
reference in its entirety. 
GRANT REFERENCE CLAUSE 
This invention was made with government support under 
Grant No. 2005-35318-15477 awarded by USDA. The gov 
ernment has certain rights in this invention. 
BACKGROUND OF THE INVENTION 
Plants produce a vast and diverse array of low-molecular 
weight organic compounds. A small number of these are 
primary metabolites, which are common to all plant species 
as they are directly required for growth and development. The 
remaining, overwhelming majority of these natural products 
are considered secondary metabolites and are not found in all 
plants. Thus, individual species produce a limited subset of all 
plant natural products, although families will sometimes 
share common secondary metabolism (e.g., oleoresinosis in 
Pinaceae). Nevertheless, many secondary metabolites have 
important ecological roles, particularly in plant defense. 
(Croteau et al. 2000). For example, phytoalexins are produced 
in response to microbial infections and exhibit antimicrobial 
properties (VanEtten et al. 1994), while allelochemicals are 
secreted to the rhiZosphere, and suppress germination and 
growth of neighboring seeds (Bais et al. 2004). 
Particularly abundant in plants, as both primary and sec 
ondary metabolites, are terpenoids, which comprise the larg 
est class of natural products and exhibit wide diversity in 
chemical structure and biological function (Croteau et al. 
2000). Much of the structural variation within this class arises 
from the diverse carbon backbones formed by terpene syn 
thases (cyclases). These divalent metal ion dependent 
enZymes carry out complex electrophilic cycliZations and/or 
rearrangements to create these diverse skeletal structures 
from relatively simple acyclic precursors (Davis and Croteau 
2000). Notably, production of a speci?c backbone structure 
either dictates, or at least severely restricts, the metabolic fate 
of that particular molecule. Thus, terpenoid biosynthesis is 
often controlled, at least in part, by regulating terpene syn 
thase activity [eg giberellin biosynthesis; (Silverstone et al. 
1 997)] . 
A substantial fraction of the known terpenoids can be clas 
si?ed as labdane-related diterpenoids (20 carbon). These are 
de?ned here as minimally containing the bicyclic hydrocar 
bon structure found in the labdane class of diterpenoids, 
although this core structure can be further cycliZed and rear 
ranged, as in the related/ derived structural classes (e. g., kau 
ranes, abietanes, and [iso]pimaranes). Signi?cantly, this 
includes the primary metabolite gibberellin growth hor 
mones. However, the vast majority of the more than 5,000 
known labdane-related diterpenoids are secondary metabo 
lites. 
Biosynthesis of labdane-related diterpenoids is initiated by 
class II terpene synthases which catalyZe formation of the 
characteristic bicyclic backbone in producing speci?c stere 
oisomers of labdadienyl/copalyl disphosphate (CPP) from 
the universal diterpenoid precursor, and plant primary 
metabolite, (E,E,E)-geranylgeranyl diphosphonate (GGPP). 
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In addition, this core bicyclic structure is always further 
modi?ed by stereoselective CPP speci?c class I terpene syn 
thases (i.e. ioniZation of the diphosphate moiety to form one 
or more new carbon-carbon bonds). Thus, class II and class I 
terpene synthases act sequentially in catalyZing stereochemi 
cally coupled cycliZation reactions to form labdane-related 
diterpene skeletal backbones. 
Signi?cantly, the class II protonation-initiated bicycliZa 
tion reaction is fundamentally different than the dipho sphate 
ioniZation initiated reactions catalyZed by the more common 
class I terpene synthases. Nevertheless, the class II cyclases 
clearly fall within the terpene synthase gene family (Bohl 
mann et al. 1998b). However, rather than the DDXXD metal 
binding motif functionally associated with class I activity 
(Davis and Croteau 2000), class II terpene cyclases contain a 
distinct DXDD motif (Sun and Kamiya 1994) which has been 
functionally associated with class II cycliZation reactions 
(Peters et al. 2001). 
Prototypical plant class I terpene synthases are similar in 
siZe and contain two structurally de?ned domains (Starks et 
al. 1997; Whittington et al. 2002). However, some terpene 
synthases, and in particular all of those involved in labdane 
related diterpenoid biosynthesis, contain a large amount of 
additional amino terminal sequence termed the ‘insertional’ 
element [approximately 240 amino acid residues; (Peters and 
Croteau 2002)]. Notably, given adequate sequence informa 
tion, this speci?c structural feature is useful for putative iden 
ti?cation of labdane-related diterpene synthases, although it 
is not suf?cient for even such generaliZed functional annota 
tion [e.g. (Bohlmann et al. 1998a)]. Rice (Oryza saliva) pro 
vides a model system to investigate labdane-related diterpe 
noid bio synthesis, as this well characterized plant is known to 
produce a number of such natural products beyond the ubiq 
uitous gibberellic acid (GA) growth hormones (FIG. 1). 
These compounds include momilactones A and B (Kato et al. 
1973; Cartwright et al. 1981), oryZalexins A to F (Akatsuka et 
al. 1985; Sekido et al. 1986; Kato et al. 1993; 1994), oryZal 
exin S (Kodama et al. 1992), and phytocassanes A to E (Koga 
et al. 1995; Koga et al. 1 997).All of these natural products are 
produced in leaves in response to infection with the blast 
pathogenic fungus Magneporlha grisea and exhibit antimi 
crobial properties; thus qualifying as phytoalexins (VanEtten 
et al. 1994). In addition, momilactones A and B also act as 
allelochemicals, as these were originally identi?ed as dor 
mancy factors from rice seed husks (Kato et al. 1973), and 
momilactone B has recently been shown to be constitutively 
secreted from the roots of rice seedlings, where it acts as an 
allelopathic agent (Kato-Noguchi and Ino 2003). Further, 
secretion of antimicrobial agents to the rhiZosphere may also 
provide a competitive advantage for root establishment 
through local suppression of soil micro-organisms (Bais et al. 
2004). 
Conveniently, rice leaves produce all of these secondary 
metabolites after UV irradiation as well as blast fungal infec 
tion (Kodama et al. 1988), providing a standard method for 
inducing bio synthesis of these natural products and, presum 
ably, transcription of the corresponding enZymatic machin 
ery. In particular, it has previously been shown that UV irra 
diation induces biosynthesis of ent-sandaracopimaradiene, 
syn-pimara-7,15-diene, and syn-stemar-13-ene, the putative 
precursors to oryZalexins A to F, momilactones A and B, and 
oryZalexin S, respectively (Wickham and West 1992). These 
polycyclic diterpene hydrocarbons further have been demon 
strated to be selectively produced via CPP of the correspond 
ing stereochemistry [i.e. ent or syn; (Mohan et al. 1996)]. 
More recent work has identi?ed the class I diterpene synthase 
producing ent-cassa-12,15-diene, the putative precursor to 
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phytocassanes A to E (Yajima et al. 2004), stereoselectively 
from ent-CPP (Cho et al. 2004). In addition, it Was also 
recently reported that only a single CPP synthase gene (Os 
CPS1) is involved in GA biosynthesis, although no sequence 
information Was presented (Sakamoto et al. 2004). Thus, 
gene function Was demonstrated by the severe groWth defect 
(i.e. dWarf phenotype) of the corresponding mutant (i.e. 
T-DNA insertion) plant, along With its rescue by exogenous 
application of GA3. Finally, although other putative class II 
and class I labdane-related diterpene synthase genes can be 
found in the rice genome, gene isolation and biochemical 
characterization have not been previously reported, leaving in 
question the role and speci?c activity of these additional 
cyclases. 
The present inventors recently identi?ed and isolated 
nucleic acid fragments encoding class II terpene synthases, as 
set forth in US. Ser. No. 11/135,267, the disclosure ofWhich 
is hereby expressly incorporated herein by reference. This 
technology has provided methods of modulating terpenoid 
biosynthesis and expression of class II terpene synthases, 
including expression of a syn-copalyl disphosphate. The class 
I genes have been designated as OsKS1-10, although only 
OsKSl actually operates in gibberellin biosynthesis and, pre 
sumably, produces ent-cassa-12,15-diene, syn-pimara-7,15 
diene, and syn-stemar-13-ene have also been termed 
OsDTC1, OsDTS2, and OsDTC2, respectively. The inventors 
have noW suggested the use of OsKSL (rice kaurene synthase 
like), With the corresponding number from Sakamoto et al. 
(2004) Where appropriate, for these non-kaurene producing 
class I genes. Thus, OsKSl presumably produced ent-kau 
rene, While OsKSL4 (OsDTS2) produces syn-pimaradiene, 
OsKSL7 (OsDTC1) ent-cassadiene, OsKSL8 (OsDTC2) 
syn-stemarene, and OsKSL10 ent-sandaracopimaradiene. 
The present inventors have noW cloned a novel stemodene 
synthase member of the described family that has hereby been 
designated OsKSL11. 
It is therefore a primary objective of the present invention 
to provide a novel diterpene synthase. 
It is a further objective of the present invention to provide 
a novel diterpene synthase designated as OsKSL11. 
It is a further objective of the present invention to provide 
a method for investigating enzymatic determinants for differ 
ential product outcome. 
It is still a further objective of the present invention to 
provide a possible means of producing stemodanes by rice. 
The method and means of accomplishing each of the above 
objectives as Well as others Will become apparent from the 
detailed description of the invention Which folloWs hereafter. 
SUMMARY OF THE INVENTION 
The present invention relates to the functional identi?ca 
tion of a novel class I diterpene synthase, OsKSL11, that is 
not present in either the genome or extensive cDNA sequence 
data available for rice. OsKSLll is a syn-CPP speci?c exo 
stemodene synthase. Rice has not previously been demon 
strated to produce stemodene or any derived natural products. 
It is, hoWever, possible that stemodante diterpenoids are pro 
duced in tissues and/or in response to other conditions, such 
as viral infection. 
In accordance With this invention, OsKSLl 1 has been iden 
ti?ed, sequenced, isolated, and biochemically characterized. 
The isolation and functional identi?cation of this diterpene 
synthase, Which is highly homologous to OsKSL8, provides 
a means of increasing the utility of the rice class I diterpene 
synthase family for examining enzymatic speci?city. 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
4 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs the knoWn cyclization steps in rice labdane 
related diterpenoid biosynthesis. Reactions catalyzed by 
class II (tpsII) or class I (tpsI) terpene synthases are indicated, 
along With the families of natural products derived from each 
of the named polycyclic hydrocarbon structures (dashed 
arroWs indicate multiple enzymatic steps). 
FIG. 2 shoWs the amino acid alignment of OSKSLl 1 With 
other functionally identi?ed rice kaurene synthase-like 
enzymes: OsKSl (SEQ ID NO: 1), OsKSL7 (SEQ ID NO: 2), 
OsKSL4 (SEQ ID NO: 3), OsKSL10 (SEQ ID NO: 4), 
OsKSLll (SEQ ID NO: 5), OsKSL8 (SEQ ID NO: 6), 
OsKSL5 (SEQ ID NO: 7), and OsKSL6 (SEQ ID NO: 8). The 
DDXXD motif is underlined. 
FIG. 3 illustrates the enzymatic products of OsKSLl 1 from 
syn-CPP. (A) GC-MS chromatograph (272 m/z extracted ion 
trace). (B) Mass spectrum of OsKSLll product peak 1 
(RT:13.23 min). (C) Mass spectrum of authentic stemod-13 
(17)-ene (RT:13.23 min). (D) Mass spectrum of OsKSL11 
product peak 2 (RT:13.10 min). (E) Mass spectrum of 
authentic stemod-12-ene (RT:13.10 min). (F) Mass spec 
trum ofOsKSLll product peak 3 (RT:13.01 min). (G) Mass 
spectrum of authentic stemar-13-ene (RT:13.01 min). 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention describes the class I diterpene syn 
thase OsKSLll that is not present in either the genome or 
extensive cDNA sequence data available for rice. Neverthe 
less, OsKSLl 1 clearly falls Within the rice kaurene synthase 
like family. 
Functional characterization of OsKSLl 1 has demonstrated 
that it is a syn-CPP speci?c exo-stemodene synthase. Rice has 
not previously been demonstrated to produce stemodene or 
any derived natural products despite intensive phytochemical 
investigations. HoWever, these studies have been almost been 
exclusively targeted at identi?cation of leaf phytoalexins, and 
it is possible that stemodane diterpenoids are produced in 
other tissues and/or in response to other conditions, such as 
viral rather than microbial infection. Interestingly, the ste 
modane and stemarene diterpene skeletal types Were both 
?rst de?ned as natural products from Slemodia maritime, a 
medicinal plant used in traditional Caribbean medicine to 
treat venereal disease. Stemodin, the major diterpenoid natu 
ral product in Slemodia, possesses antiviral activity, Which 
may help account for the use of this plant as an herbal medi 
cine and, more generally, for the function of this natural 
product in plants. Nevertheless, nothing is knoWn about the 
enzymatic genes involved in biosynthesis of the Slemodia 
diterpenoid natural products, and OsKSLl 1 appears to be the 
?rst identi?ed stemodene synthase. 
Formation of the stemodene and stemarene backbones can 
be envisioned as arising from largely overlapping cyclization 
mechanisms. In particular, initial cyclization of syn-CPP to 
an isopimarenyl intermediate that undergoes a 1,2-hydride 
shift from C9 to C8, folloWed by further cyclization to an 
abeo-stachanyl intermediate. Alternative ring rearrange 
ments can then form either stemodenyl or stemarenyl inter 
mediates that undergo deprotonation to yield the ?nal tetra 
cyclic diterpenes. The highly homologous OsKSLll and 
OsKSL8 presumably catalyze these alternative, yet mecha 
nistically related, cyclization reactions. Hence, structure 
function analysis of this pair of cyclases should facilitate 
identi?cation of the underlying enzymatic determinants for 
this relatively subtle change in product outcomes. In fact, 
OsKSLll and OsKSL8 seem to be the most closely related 
US 7,833,748 B1 
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pair of rice class I diterpene synthases (89% amino acid 
identity). Thus, identi?cation of OsKSLll measurably 
increases the utility of the rice class I diterpene synthase 
family for examining enzymatic speci?city. 
The existence of OsKSLll indicates that rice has the 
capacity to produce stemodene. However, rice has not been 
shoWn to produce stemodane type diterpenoid natural prod 
ucts. Nevertheless, While even latent, currently untapped 
potential may offer some advantage in plasticity of natural 
products biosynthesis, the production of stemodanes by rice 
cannot be ruled out. It has recently been observed that Ara 
bidopsis Zhaliana is capable of producing a much Wider range 
of natural products than Was previously appreciated. 
As used here, the term “isolated” means any class I diter 
pene synthase of the present invention, or any gene encoding 
a class I diterpene synthase, Which is essentially free of other 
polypeptides or genes, respectively, or of other contaminants 
With Which the class I diterpene synthase polypeptide or gene 
might normally be found in nature. 
The invention includes a functional polypeptide, OsKSLl 1 
and functional fragments thereof. As used herein, the term 
“functional polypeptide” refers to a polypeptide Which pos 
sesses a biological function or activity Which is identi?ed 
through a de?ned functional assay and Which is associated 
With a particular biologic, morphologic, or phenotypic alter 
ation in the cell. The biological function, for example, can 
vary from a polypeptide fragment as small as an epitope to 
Which an antibody molecule can bind to a large polypeptide 
Which is capable of participating in the characteristic induc 
tion or programming of phenotypic changes Within a cell. A 
“functional polynucleotide” denotes a polynucleotide Which 
encodes a functional polypeptide as described herein. 
Minor modi?cations of the primary amino acid sequences 
of the terpene synthases of this invention may result in pro 
teins Which have substantially equivalent activity as com 
pared to the polypeptides described herein. Such modi?ca 
tions may be deliberate, as by site-directed mutagenesis, or 
may be spontaneous. All of the polypeptides produced by 
these modi?cations are included herein as long as the 
described activities of the terpene synthases are present. Fur 
ther, deletion of one or more amino acids can also result in a 
modi?cation of the structure of the resultant molecule With 
out signi?cantly altering its biological activity. This can lead 
to the development of a smaller active molecule Which Would 
have broader utility. For example, it is possible to remove 
amino or carboxy terminal amino acids Which may not be 
required for biological activity. 
The polypeptides of the invention also include conserva 
tive variations of the polypeptide sequences. The term “con 
servative variation” as used herein denotes the replacement of 
an amino acid residue by another, biologically similar resi 
due. Examples of conservative variations include the substi 
tution of one hydrophobic residue such as isoleucine, valine, 
leucine or methionine for another, or the substitution of one 
polar residue for another, such as the substitution of arginine 
for lysine, glutamic for aspartic acids, or glutamine for aspar 
agine, and the like. The term “conservative variation” also 
includes the use of a substituted amino acid in place of an 
unsubstituted parent amino acid provided that antibodies 
raised to the substituted polypeptide also immunoreact With 
the unsubstituted polypeptide. 
The invention is also intended to include synthetic pep 
tides. The amino acid sequence of SEQ ID NO: 5 (FIG. 2), 
and conservative variations, comprise the synthetic peptides 
of the invention. As used herein, the term “synthetic peptide” 
denotes a peptide Which does not comprise an entire naturally 
occurring protein molecule. The peptide is “synthetic” in that 
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it may be produced by human intervention using such tech 
niques as chemical synthesis, recombinant genetic tech 
niques, or fragmentation of Whole antigen or the like. 
Peptides of the invention can be synthesiZed by such com 
monly used methods as t-BOC or FMOC protection of alpha 
amino groups. Both methods involve stepWise syntheses 
Whereby a single amino acid is added at each step starting 
from the C-terminus of the peptide (See, Coligan, et al., 
Current Protocols in Immunology, Wiley Interscience, 1991, 
Unit 9). Peptides of the invention can also be synthesiZed by 
the Well knoWn solid phase peptide synthesis methods 
described in Merri?eld, J. Am. Chem. Soc., 8512149, 1962, 
and SteWart and Young, Solid Phase Peptides Synthesis, 
(Freeman, San Francisco, 1969, pp. 27-62), using a copoly 
(styrene-divinylbenZene) containing 0.1-1.0 mMol amines/ g 
polymer. On completion of chemical synthesis, the peptides 
can be deprotected and cleaved from the polymer by treat 
ment With liquid HF-10% anisole for about 1/4-1 hours at 00 C. 
After evaporation of the reagents, the peptides are extracted 
from the polymer With 1% acetic acid solution Which is then 
lyophiliZed to yield the crude material. This can normally be 
puri?ed by such techniques as gel ?ltration on Sephadex G-15 
using 5% acetic acid as a solvent. LyophiliZation of appropri 
ate fractions of the column Will yield the homogeneous pep 
tide or peptide derivatives, Which can then be characterized by 
such standard techniques as amino acid analysis, thin layer 
chromatography, high performance liquid chromatography, 
ultraviolet absorption spectroscopy molar, rotation, solubil 
ity, and quantitated by the solid phase Edman degradation. 
As used herein, “polynucleotide” refers to a polymer of 
deoxyribonucleotides or ribonucleotides, in the form of a 
separate fragment or as a component of a larger construct. As 
used herein, “percentage of sequence identity” means the 
value determined by comparing tWo optimally aligned 
sequences over a comparison WindoW, Wherein the portion of 
the polynucleotide sequence in the comparison WindoW may 
comprise additions or deletions (i.e., gaps) as compared to the 
reference sequence (Which does not comprise additions or 
deletions) for optimal alignment of the tWo sequences. The 
percentage is calculated by determining the number of posi 
tions at Which the identical nucleic acid base or amino acid 
residue occurs in both sequences to yield the number of 
matched positions, dividing the number of matched positions 
by the total number of positions in the WindoW of comparison 
and multiplying the result by 100 to yield the percentage of 
sequence identity. 
The term “substantial identity” of polynucleotide 
sequences means that a polynucleotide comprises a sequence 
that has betWeen 50-100% sequence identity, preferably at 
least 50% sequence identity, preferably at least 60% sequence 
identity, preferably at least 70%, more preferably at least 
80%, more preferably at least 90% and most preferably at 
least 95%, compared to a reference sequence using one of the 
alignment programs described using standard parameters. 
One of skill Will recogniZe that these values can be appropri 
ately adjusted to determine corresponding identity of proteins 
encoded by tWo nucleotide sequences by taking into account 
codon degeneracy, amino acid similarity, reading frame posi 
tioning and the like. Substantial identity of amino acid 
sequences for these purposes normally means sequence iden 
tity of betWeen 55-100%, preferably at least 55%, preferably 
at least 60%, more preferably at least 70%, 80%, 90%, and 
most preferably at least 95%. 
DNA encoding the polypeptide of the invention can be 
assembled from cDNA fragments or from oligonucleotides 
Which provide a synthetic gene Which is capable of being 
expressed in a recombinant transcriptional unit. Polynucle 
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otide sequences of the invention include DNA, RNA and 
cDNA sequences. Preferably, the nucleotide sequence encod 
ing the diterpene synthase of this invention has the sequence 
of SEQ ID NO: 5. 
DNA sequences of the invention can be obtained by several 
methods. For example, the DNA can be isolated using hybrid 
ization procedures Which are Well knoWn in the art. These 
include, but are not limited to: l) hybridization of probes to 
genomic or cDNA libraries to detect shared nucleotide 
sequences; 2) antibody screening of expression libraries to 
detect shared structural features and 3) synthesis by the poly 
merase chain reaction (PCR). 
Hybridization procedures are useful for the screening of 
recombinant clones by using labeled mixed synthetic oligo 
nucleotide probes Where each probe is potentially the com 
plete complement of a speci?c DNA sequence in the hybrid 
ization sample Which includes a heterogeneous mixture of 
denatured double-stranded DNA. For such screening, hybrid 
ization is preferably performed on either single-stranded 
DNA or denatured double-stranded DNA. Hybridization is 
particularly useful in the detection of cDNA clones derived 
from sources Where an extremely loW amount of mRNA 
sequences relating to the polypeptide of interest are present. 
In other Words, by using stringent hybridization conditions 
directed to avoid non-speci?c binding, it is possible, for 
example, to alloW the autoradiographic visualization of a 
speci?c cDNA clone by the hybridization of the target DNA 
to that single probe in the mixture Which is its complete 
complement (Wallace, et al., Nucleic Acid Research, 9:879, 
l 981). 
The development of speci?c DNA sequences encoding 
OsKSLll can also be obtained by: l) isolation of double 
stranded DNA sequences from the genomic DNA; 2) chemi 
cal manufacture of a DNA sequence to provide the necessary 
codons for the polypeptide of interest; and 3) in vitro synthe 
sis of a double-stranded DNA sequence by reverse transcrip 
tion of mRNA isolated from a eukaryotic donor cell. In the 
latter case, a double-stranded DNA complement of mRNA is 
eventually formed Which is generally referred to as cDNA. Of 
these three methods for developing speci?c DNA sequences 
for use in recombinant procedures, the isolation of genomic 
DNA isolates is the least common. 
The synthesis of DNA sequences is frequently the method 
of choice When the entire sequence of amino acid residues of 
the desired polypeptide product is knoWn. When the entire 
sequence of amino acid residues of the desired polypeptide is 
not knoWn, the direct synthesis of DNA sequences is not 
possible and the method of choice is the synthesis of cDNA 
sequences. Among the standard procedures for isolating 
cDNA sequences of interest is the formation of plasmid- or 
phage-carrying cDNA libraries Which are derived from 
reverse transcription of mRNA Which is abundant in donor 
cells that have a high level of genetic expression. When used 
in combination With polymerase chain reaction technology, 
even rare expression products can be cloned. In those cases 
Where signi?cant portions of the amino acid sequence of the 
polypeptide are knoWn, the production of labeled single or 
double-stranded DNA or RNA probe sequences duplicating a 
sequence putatively present in the target cDNA may be 
employed in DNA/ DNA hybridization procedures Which are 
carried out on cloned copies of the cDNA Which have been 
denatured into a single-stranded form (Jay et al., Nucl. Acid 
Res. 1112325, 1983). 
A cDNA expression library, such as lambda gt 11, can be 
screened indirectly for polypeptides having at least one 
epitope, using antibodies speci?c for class I diterpene syn 
thases. Such antibodies can be either polyclonally or mono 
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clonally derived andused to detect expression product indica 
tive of the presence of diterpene synthase cDNA. 
A polynucleotide sequence can be deduced from the 
genetic code. HoWever, the degeneracy of the code must be 
taken into account. Polynucleotides of the invention include 
sequences Which are degenerate as a result of the genetic 
code. The polynucleotides of the invention include sequences 
that are degenerate as a result of the genetic code. There are 20 
natural amino acids, mo st of Which are speci?ed by more than 
one codon. Therefore, as long as the amino acid sequences of 
the class II terpene synthases results in a functional polypep 
tide (at least, in the case of the sense polynucleotide strand), 
all degenerate nucleotide sequences are included in the inven 
tion. 
The polynucleotide sequences for the diterpene synthases 
of this invention also include sequences complementary to 
the polynucleotide encoding these terpene synthases (anti 
sense sequences). Antisense nucleic acids are DNA or RNA 
molecules that are complementary to at least a portion of a 
speci?c mRNA molecule (Weintraub, Scienti?c American, 
262:40, 1990). The invention embraces all antisense poly 
nucleotides capable of inhibiting production of diterpene syn 
thase polypeptides. In the cell, the antisense nucleic acids 
hybridize to the corresponding mRNA, forming a double 
stranded molecule. The antisense nucleic acids interfere With 
the translation of the mRNA since the cell Will not translate an 
mRNA that is double-stranded. Antisense oligomers of about 
15 nucleotides are preferred, since they are easily synthesized 
and are less likely to cause problems than larger molecules 
When introduced into the target terpene synthase-producing 
cell. The use of antisense methods to inhibit the translation of 
genes is Well known in the art (Marcus-Sakura, Anal. Bio 
chem., 172:289, 1988). 
In addition, ribozyme nucleotide sequences for OsKSLll 
are included in the invention. Ribozymes are RNA molecules 
possessing the ability to speci?cally cleave other single 
stranded RNA in a manner analogous to DNA restriction 
endonucleases. Through the modi?cation of nucleotide 
sequences Which encode these RNAs, it is possible to engi 
neer molecules that recognize speci?c nucleotide sequences 
in an RNA molecule and cleave it (Cech, J. Amer. Med. Assn., 
260:3030, 1988). A major advantage of this approach is that, 
because they are sequence-speci?c, only mRNAs With par 
ticular sequences are inactivated. 
The polypeptides of the invention can also be used to 
produce antibodies Which are immunoreactive or bind to 
epitopes of the terpene synthase polypeptides. Antibodies of 
the invention also include antibodies Which bind to the syn 
thetic peptides in SEQ ID NO: 5 (FIG. 2). Antibodies Which 
consist essentially of pooled monoclonal antibodies With dif 
ferent epitopic speci?cities, as Well as distinct monoclonal 
antibody preparations are provided. Monoclonal antibodies 
are made from antigen containing fragments of the protein by 
methods Well knoWn in the art (Kohler, et al., Nature, 256: 
495, 1975; Current Protocols in Molecular Biology, Ausubel, 
et al., ed., 1989). 
As used in this invention, the term “epitope” means any 
antigenic determinant on an antigen to Which the paratope of 
an antibody binds. Epitopic determinants usually consist of 
chemically active surface groupings of molecules such as 
amino acids or sugar side chains and usually have speci?c 
three dimensional structural characteristics, as Well as spe 
ci?c charge characteristics. 
Antibodies Which bind to the polypeptides of the invention 
can be prepared using an intact polypeptide or fragments 
containing small peptides of interest as the immunizing anti 
gen. The polypeptides or peptides such as SEQ ID NO: 5 can 
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be derived from translated cDNA or chemical synthesis 
Which can be conjugated to a carrier protein, if desired. Such 
commonly used carriers Which are chemically coupled to the 
peptide include keyhole limpet hemocyanin (KLH), thyro 
globulin, bovine serum albumin (BSA), and tetanus toxoid. 
The coupled peptide is then used to immuniZe the animal 
(e.g., a mouse, a rat, or a rabbit). 
If desired, polyclonal or monoclonal antibodies can be 
further puri?ed, for example, by binding to and elution from 
a matrix to Which the polypeptide or a peptide to Which the 
antibodies Were raised is bound. Those skilled in the art Will 
knoW of various techniques common in the immunology arts 
for puri?cation and/ or concentration of polygonal antibodies, 
as Well as monoclonal antibodies (See for example, Coligan, 
et al., Unit 9, Current Protocols in Immunology, Wiley Inter 
science, 1991, incorporated by reference). 
It is also possible to use the anti-idiotype technology to 
produce monoclonal antibodies Which mimic an epitope. For 
example, an anti-idiotypic monoclonal antibody made to a 
?rst monoclonal antibody Will have a binding domain in the 
hypervariable region Which is the “image” of the epitope 
bound by the ?rst monoclonal antibody. 
Polynucleotide sequences encoding the polypeptide (SEQ 
ID NO: 5) of the invention can be expressed in either prokary 
otes or eukaryotes. Hosts can include microbial, yeast, insect 
and mammalian organisms. Methods of expressing DNA 
sequences having eukaryotic or viral sequences in prokary 
otes are Well knoWn in the art. Biologically functional viral 
and plasmid DNA vectors capable of expression and replica 
tion in a host are knoWn in the art. Such vectors are used to 
incorporate DNA sequences of the invention. 
DNA sequences encoding the polypeptides can be 
expressed in vitro by DNA transfer into a suitable host cell. 
“Host cells” are cells in Which a vector can be propagated and 
its DNA expressed. The term also includes any progeny of the 
subject host cell. It is understood that all progeny may not be 
identical to the parental cell since there may be mutations that 
occur during replication. HoWever, such progeny are included 
When the term “host cell” is used. Methods of stable transfer, 
in other Words When the foreign DNA is continuously main 
tained in the host, are knoWn in the art. 
In the present invention, the diterpene synthase polynucle 
otide sequences may be inserted into a recombinant expres 
sion vector. The term “recombinant expression vector” refers 
to a plasmid, virus or other vehicle knoWn in the art that has 
been manipulated by insertion or incorporation of the genetic 
sequences. Such expression vectors contain a promoter 
sequence Which facilitates the ef?cient transcription of the 
inserted genetic sequence of the host. The expression vector 
typically contains an origin of replication, a promoter, as Well 
as speci?c genes Which alloW phenotypic selection of the 
transformed cells. Vectors suitable for use in the present 
invention include, but are not limited to the T7-based expres 
sion vector for expression in bacteria (Rosenberg et al., Gene 
56:125, 1987), the pMSXND expression vector for expres 
sion in mammalian cells (Lee and Nathans, J. Biol. Chem. 
263:3521, 1988) and baculovirus-derived vectors for expres 
sion in insect cells. The DNA segment can be present in the 
vector operably linked to regulatory elements, for example, a 
promoter (e.g., T7, metallothionein I, or polyhedrin promot 
ers). 
The vector may include a phenotypically selectable marker 
to identify host cells Which contain the expression vector. 
Examples of markers typically used in prokaryotic expres 
sion vectors include antibiotic resistance genes for ampicillin 
([3-lactamases), tetracycline and chloramphenicol (chloram 
phenicol acetyl-transferase). Examples of such markers typi 
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cally used in mammalian expression vectors include the gene 
for adenosine deaminase (ADA), aminoglycoside phospho 
transferase (neo, G418), dihydrofolate reductase (DHFR), 
hygromycin-B-phosphotransferase (HPH), thymidine kinase 
(TK), and xanthine guanine phosphoribosyltransferse (XG 
PRT, gpt). 
Transformation of a host cell With recombinant DNA may 
be carried out by conventional techniques Which are Well 
knoWn to those skilled in the art. Where the host is prokary 
otic, such as E. coli, competent cells Which are capable of 
DNA uptake can be prepared from cells harvested after expo 
nential groWth phase and subsequently treated by the CaCl2 
method by procedures Well knoWn in the art. Alternatively, 
MgCl2 or RbCl can be used. Transformation can also be 
performed after forming a protoplast of the host cell or by 
electroporation. 
When the ho st is a eukaryote, such methods of transfection 
of DNA as calcium phosphate co-precipitates, conventional 
mechanical procedures such as microinjection, electropora 
tion, insertion of a plasmid encased in liposomes, or virus 
vectors may be used. Eukaryotic cells can also be cotrans 
formed With DNA sequences encoding the polypeptides of 
the invention, and a second foreign DNA molecule encoding 
a selectable phenotype, such as the herpes simplex thymidine 
kinase gene. Another method is to use a eukaryotic viral 
vector, such as simian virus 40 (SV40) or bovine papilloma 
virus, to transiently infect or transform eukaryotic cells and 
express the protein. (Eukaryotic Viral Vectors, Cold Spring 
Harbor Laboratory, GluZman ed., 1982). Examples of mam 
malian host cells include COS, BHK, 293, and CHO cells. 
Isolation and puri?cation of host cell expressed polypep 
tide, or fragments thereof, provided by the invention, may be 
carried out by conventional means including preparative 
chromatography and immunological separations involving 
monoclonal or polyclonal antibodies. 
The class I diterpene synthases of the invention are useful 
in a screening method for identifying compounds or compo 
sitions Which affect the activity of the synthases. Thus, in 
another embodiment, the invention provides a method for 
identifying a composition Which affects a class I diterpene 
synthase of this invention comprising incubating the compo 
nents, Which include the composition to be tested and the 
synthase or a polynucleotide encoding the synthase, under 
conditions su?icient to alloW the components to interact, then 
subsequently measuring the effect the composition has on 
synthase activity or on the polynucleotide encoding the syn 
thase. The observed effect on the synthase may be either 
inhibitory or stimulatory. A polynucleotide encoding the 
kinase may be inserted into an expression vector and the 
effect of a composition on transcription of the kinase can be 
measured, for example, by Northern blot analysis. 
Another embodiment provides a method for engineering 
production of syn-CPP or other molecules of the invention 
either ex vivo or in genetically-engineered organisms. In this 
respect, using the nucleic acids of the present invention, one 
may express a protein of the present invention in a recombi 
nantly engineered cell such as bacteria, yeast, insect, mam 
malian, or preferably plant cells. The cells produce the protein 
in a non-natural condition (e.g., in quantity, composition, 
location, and/or time), because they have been genetically 
altered through human intervention to do so. It is expected 
that those of skill in the art are knoWledgeable in the numer 
ous expression systems available for expression of a nucleic 
acid encoding a protein of the present invention. No attempt 
to describe in detail the various methods knoWn for the 
expression of proteins in prokaryotes or eukaryotes Will be 
made. 
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In brief summary, the expression of isolated nucleic acids 
encoding a protein of the present invention Will typically be 
achieved by operably linking, for example, the DNA or cDNA 
to a promoter (Which is either constitutive or inducible), fol 
loWed by incorporation into an expression vector. The vectors 
can be suitable for replication and integration in either 
prokaryotes or eukaryotes. Typical expression vectors con 
tain transcription and translation terminators, initiation 
sequences, and promoters useful for regulation of the expres 
sion of the DNA encoding a protein of the present invention. 
To obtain high level expression of a cloned gene, it is desir 
able to construct expression vectors Which contain, at the 
minimum, a strong promoter, such as ubiquitin, to direct 
transcription, a ribosome binding site for translational initia 
tion, and a transcription/translation terminator. Constitutive 
promoters are classi?ed as providing for a range of constitu 
tive expression. Thus, some are Weak constitutive promoters, 
and others are strong constitutive promoters. Generally, by 
“Weak promoter” is intended a promoter that drives expres 
sion of a coding sequence at a loW level. By “loW level” is 
intended at levels of about I/ 10,000 transcripts to about 
I/ 100,000 transcripts to about I/ 500,000 transcripts. Con 
versely, a “strong promoter” drives expression of a coding 
sequence at a “high level”, or about 1/10 transcripts to about 
I/ 100 transcripts to about I/ 1,000 transcripts. 
One of skill Would recogniZe that modi?cations could be 
made to a protein of the present invention Without diminish 
ing its biological activity. Some modi?cations may be made 
to facilitate the cloning, expression, or incorporation of the 
targeting molecule into a fusion protein. Such modi?cations 
are Well knoWn to those of skill in the art and include, for 
example, a methionine added at the amino terminus to pro 
vide an initiation site, or additional amino acids (e.g., poly 
His) placed on either terminus to create conveniently located 
restriction sites or termination codons or puri?cation 
sequences. 
In another embodiment, the invention provides a method of 
modulating GA phytohorrnone and/or defensive phytoalexin 
biosynthesis in plants comprising administering an amount of 
reagent effective in modulating synthase activity. The term 
“effective amount” means that amount of monoclonal anti 
body or antisense nucleotide, for example, Which is used, is of 
suf?cient quantity to modulate terpene synthase activity. 
Treatment includes administration of a reagent Which 
modulates terpene synthase activity. The term “modulate” 
envisions the suppression of expression of the synthase When 
it is over-expressed, or augmentation of terpene synthase 
expression When it is under-expressed. It also envisions sup 
pression of terpene synthase activity, for example, by using a 
competitive inhibitor of the natural synthase binding site in a 
cell. When a disorder is associated With synthase overexpres 
sion, such suppressive reagents as antisense polynucleotide 
sequences or binding antibodies can be introduced to a cell or 
plant. In addition, an anti-idiotype antibody Which binds to a 
monoclonal antibody Which binds a peptide of the invention 
may also be used in the therapeutic method of the invention. 
Alternatively, When a cell proliferative disorder is associated 
With underexpression or expression of a mutant polypeptide, 
a sense polynucleotide sequence (the DNA coding strand) or 
polypeptide can be introduced into the cell. 
Peptides, antibodies, and polynucleotide sequences, 
including antisense sequences, can be therapeutically admin 
istered by various techniques knoWn to those of skill in the art. 
Such therapy Would achieve its therapeutic effect by intro 
duction of the polynucleotide, into cells of plants having the 
proliferative disorder. Delivery of polynucleotide can be 
achieved using free polynucleotide or a recombinant expres 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
12 
sion vector such as a chimeric virus or a colloidal dispersion 
system. Especially preferred for therapeutic delivery of 
nucleotide sequences is the use of targeted liposomes. 
Various viral vectors Which can be utiliZed for gene therapy 
as taught herein include adenovirus, herpes virus, vaccinia, 
or, preferably, an RNA virus such as a retrovirus. Preferably, 
the retroviral vector is a derivative of a murine or avian 
retrovirus. Examples of retroviral vectors in Which a single 
foreign gene can be inserted include, but are not limited to: 
Moloney murine leukemia virus (MoMuLV), Harvey murine 
sarcoma virus (HaMuSV), murine mammary tumor virus 
(MuMTV), and Rous Sarcoma Virus (RSV). A number of 
additional retroviral vectors can incorporate multiple genes. 
All of these vectors can transfer or incorporate a gene for a 
selectable marker so that transduced cells can be identi?ed 
and generated. By inserting a terpene synthase sequence into 
the viral vector, along With another gene Which encodes the 
ligand for a receptor on a speci?c target cell, for example, the 
vector is noW target speci?c. Retroviral vectors can be made 
target speci?c by inserting, for example, a polynucleotide 
encoding a sugar, a glycolipid, or a protein. Preferred target 
ing is accomplished by using an antibody to target the retro 
viral vector. Those of skill in the art Will knoW of, or can 
readily ascertain Without undue experimentation, speci?c 
polynucleotide sequences Which can be inserted into the ret 
roviral genome to alloW target speci?c delivery of the retro 
viral vector containing the polynucleotide. 
Since recombinant retroviruses are defective, they require 
assistance in order to produce infectious vectorparticles. This 
assistance can be provided, for example, by using helper cell 
lines that contain plasmids encoding all of the structural 
genes of the retrovirus under the control of regulatory 
sequences Within the LTR. These plasmids are missing a 
nucleotide sequence Which enables the packaging mecha 
nism to recogniZe an RNA transcript for encapsitation. 
Helper cell lines Which have deletions of the packaging signal 
include but are not limited to psi2, PA3l7 and PAl2, for 
example. These cell lines produce empty virions, since no 
genome is packaged. If a retroviral vector is introduced into 
such cells in Which the packaging signal is intact, but the 
structural genes are replaced by other genes of interest, the 
vector can be packaged and vector virion produced. The 
vector virions produced by this method can then be used to 
infect a tissue cell line, such as NIH 3T3 cells, to produce 
large quantities of chimeric retroviral virions. 
Another targeted delivery system for polynucleotides is a 
colloidal dispersion system. Colloidal dispersion systems 
include macromolecule complexes, nanocapsules, micro 
spheres, beads, and lipid-based systems including oil-in-Wa 
ter emulsions, micelles, mixed micelles, and liposomes. A 
preferred colloidal system of this invention is a liposome. 
Liposomes are arti?cial membrane vesicles Which are useful 
as delivery vehicles in vitro and in vivo. It has been shoWn that 
large unilamellar vesicles (LUV), Which range in siZe from 
0.2-4.0 um can encapsulate a substantial percentage of an 
aqueous buffer containing large macromolecules. RNA, 
DNA and intact virions can be encapsulated Within the aque 
ous interior and be delivered to cells in a biologically active 
form (Fraley, et al., Trends Biochem. Sci., 6:77, 1981). In 
addition to plant cells, liposomes have been used for delivery 
of polynucleotides in animal, yeast and bacterial cells. In 
order for a liposome to be an e?icient gene transfer vehicle, 
the folloWing characteristics should be present: (1) encapsu 
lation of the genes of interest at high e?iciency While not 
compromising their biological activity; (2) preferential and 
substantial binding to a target cell in comparison to non-target 
cells; (3) delivery of the aqueous contents of the vesicle to the 
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target cell cytoplasm at high e?iciency; and (4) accurate and 
effective expression of genetic information (Mannino, et al., 
Biotechniques, 6:682, 1988). 
The invention also provides a method for detecting a cell 
With diterpene synthase activity or a cell proliferative disor 
der associated With terpenoids comprising contacting a cell 
component With terpene synthase activity With a reagent 
Which binds to the component and measuring the interaction 
of the reagent With the component. Such reagents can be used 
to measure relative levels of terpenoid expression compared 
to normal tissue. The cell component can be nucleic acid, 
such as DNA or RNA, or protein. When the component is 
nucleic acid, the reagent is a nucleic acid probe or PCR 
primer. The interaction of a nucleic acid reagent With a 
nucleic acid encoding a polypeptide With terpene synthase 
activity is typically measured using radioactive labels, hoW 
ever, other types of labels Will be knoWn to those of skill in the 
art. When the cell component is protein, the reagent is typi 
cally an antibody probe. The probes are directly or indirectly 
detectably labeled, for example, With a radioisotope, a ?uo 
rescent compound, a bioluminescent compound, a chemilu 
minescent compound, a metal chelator or an enzyme. Those 
of ordinary skill in the art Will knoW of other suitable labels 
for binding to the antibody, or Will be able to ascertain such, 
using routine experimentation. 
The materials of the invention are ideally suited for the 
preparation of a kit. The kit is useful for the detection of the 
level of a diterpene synthase comprising an antibody Which 
binds a terpene synthase or a nucleic acid probe Which hybrid 
izes to terpenoid nucleotide, the kit comprising a carrier 
means being compartmentalized to receive in close con?ne 
ment therein one or more containers such as vials, tubes, and 
the like, each of the container means comprising one of the 
separate elements to be used in the assay. For example, one of 
the container means may comprise a monoclonal antibody of 
the invention Which is, or can be, detectably labeled. The kit 
may also have containers containing buffer(s) and/or a con 
tainer comprising a reporter-means (for example, a biotin 
binding protein, such as avidin or streptavidin) bound to a 
reporter molecule (for example, an enzymatic or ?uorescent 
label). 
The folloWing example is offered to illustrate but not limit 
the invention. Thus, they are presented With the understand 
ing that various modi?cations may be made and still be Within 
the spirit of the invention. 
Example 1 
Functional Identi?cation of OsKSLll 
Chemicals. The preparations of (E,E,E)-geranylgeranyl 
diphosphate (GGPP), and ent- and syn-copalyl diphosphate 
(CPP), and syn-stemarene have been previously described. 
(Mohan et al. 1996). Stemodene standards Were derived from 
a 1.511 mixture (ca. 5 mg) of synthetic racemic exo- and 
endo-stemodenes, kindly provided by Jim White. (White et 
al. 1994). This Was fractionated by ?ash chromatography on 
a silica gel column (1 cm><10 cm) using pentane and the later 
eluting fractions (enriched for the exo isomer) Were pooled 
and concentrated under nitrogen to yield ~2 mg exo-ste 
modene (~85% purity by GC analysis). Unless otherWise 
noted, chemicals Were purchased from Fisher Scienti?c 
(Loughborough, Leicestershire, UK) and molecular biology 
reagents from lnvitrogen (Carlsbad, Calif., USA). 
Plant material. Rice plants (Oryza saliva L. ssp. indica cv. 
IR24) and seedlings (ssp. japonica cv Nipponbare) Were those 
previously described. @(u et al. 2004). Detached leaves from 
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4-Week-old greenhouse groWn plants Were UV-irradiated 
(254 nm from 15-cm distance for 25 min.) and then incubated 
for 24 h under dark, humid conditions at 30° C. Seedlings 
Were germinated from surface sterilized seeds on ?lter paper 
in sterile 1.2% agar plates at 30° C. in the dark for a Week, then 
sprayed With approximately 2 mL 0.1% TWeen 20 With 0.5 
mM methyl jasmonate per gram of plant Weight, and incu 
bated 24 h under the same conditions. The resulting tissues 
Were frozen in liquid nitrogen and total RNA extracted using 
Concert Plant RNA Reagent, folloWing the manufacturer’s 
instructions. 
Cloning. Using the predicted sequence from GenBank 
Accession No. AK108710 a 5' primer (CACCATGATGCT 
GCTGAGTTCCTC) (SEQ ID NO: 9) Was designed and 
employed in a 3' RACE reaction (GeneRacer), using RNA 
from UV-induced indica leaves, to amplify a cDNA product 
of 2703 nucleotides. This Was cloned into pCR4-ZeroBlunt, 
and completely sequenced. The derived sequence Was further 
con?rmed by cloning an identical open reading frame (2451 
nucleotides) from methyl jasmonate-induced japonica seed 
lings by RT-PCR using the 5' primer described above and a 3' 
primer (TTACTCTTGCAGGTGCAGTGGCTC) (SEQ ID 
NO: 10). This sequence has been deposited as OsKSLll in 
the various DNA databases as Accession DQ100373. Full 
length and N-terminally truncated (by 60 residues) versions 
of OsKSLll Were constructed in pENTR/SD/D-TOPO 
(GateWay system) and veri?ed by complete sequencing. 
These Were then transferred by directional recombination to 
the T7-based, glutathione-S-transferase (GST) fusion expres 
sion vector pDEST15 (GateWay systems). 
Recombinant expression. Recombinant expression Was 
carried out in the BL21 derived strain C41 (Miroux and 
Walker 1996). Brie?y, NZY media cultures Were groWn to 
midlog phase at 37° C. (OD6OO~0.6) then shifted to 16° C. for 
1 h prior to induction (With 1 mM IPTG) and overnight 
expression. Cells Were harvested by centrifugation, resus 
pended in cold lysis buffer 50 mM Bis-Tris, pH 6.8, 1 mM 
DTT), lysed by mild sonication on ice (15 s, continuous 
output, setting 5), and clari?ed by centrifugation (40,000 g, 
20 min). The recombinant GST-tagged protein Was puri?ed 
using GST-agarose beads (Sigma-Aldrich). SDS-PAGE 
analysis demonstrated that only a single band of the appro 
priate molecular Weight Was obtained. 
Functional characterization. Assays Were generally carried 
out With 5 ug of substrate (GGPP, syn-CPP or ent-CPP) and 
25 pL of recombinant protein in 0.5 mL of assay buffer (50 
mM Hepes, pH 7.2, 10 mM MgCl2, 10% glycerol, and 5 mM 
DTT) for 3-16 h at room temperature. The assay solutions 
Were extracted three times With 0.5 mL portions of hexanes, 
Which Were pooled, dried under a gentle stream of nitrogen, 
and re-dissolved in 100 pL of hexanes. Gas chromatography 
mass spectrometry (GC-MS) analysis Was carried out using 
an HP-5MS column on an Agilent (Palo Alto, Calif.) 6890N 
GC instrument With a 5973N mass selective detector. 
Samples (5 uL) Were injected at 40° C. in the splitless mode 
and, after holding 3 min at 40° C., the temperature Was 
increased at 20° C./min to 300° C., Where it Was also held for 
3 min. MS data Were collected from 50 to 500 m/z during the 
temperature ramp. Larger amounts of product Were obtained 
from GGPP using coupled assays With puri?ed GST 
OsKSLll and the truncated and GST-tagged version of 
OsCPS4 that has been previously described @(u et al. 2004) 
Which Was expressed and puri?ed as described above for 
GST-OsKSLll. The resulting hexane-benzene extract (~1 
mL) containing the diterpene products Was shipped to the 
University of Illinois on dry ice for NMR spectroscopy. The 
solution Was ?ltered through a short silica gel column With 
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pentane and then concentrated under a N2 stream to ca. 0.1 
mL and re-dissolved in 1 mL of C6D6. The evaporation 
dissolution Was repeated four times to completely remove the 
hexane and protonated benzene solvents. Proton NMR spec 
tra Were recorded in C6D6 (to reduce the risk of air oxidation) 
using aVarian 500 MHZ spectrometer in the School of Chemi 
cal Sciences NMR spectroscopy facility at the University of 
Illinois. 
Sequence analysis. BLAST searches Were carried out on 
line at either GenBank (WWW.ncbi.nih. gov), TIGR (WWW.ti 
gr.org), or Gramene (WWW. gramene.org). All other sequence 
analysis Was performed With the AlignX program in the Vec 
tor NTI software package (Invitrogen) using standard param 
eters. OsKSl Was designated as the reference sequence in all 
alignments. 
Results 
Cloning an unexpected class I terpene synthase. A putative 
class I labdane-related diterpene synthase gene, predicted 
from the rice genome sequence, Was found in GenBank 
Accession No. AK108710. Surprisingly, When it Was 
attempted to clone the corresponding cDNA, the isolated 
sequence did not correspond to that found in AK108710, 
although the tWo Were ~92% identical at the nucleotide level. 
In fact, corresponding sequence could not be found in cur 
rently available rice genome or expressed sequence tag data, 
although the inventors Were able to clone this cDNA from 
both spp. indica and japonica rice. The isolated cDNA does 
contain an open reading frame that encodes a class I diterpene 
synthase (i.e., had the large “insertional” element and 
DDXXD motif) that Was highly homologous (42-89% amino 
acid identity) to the known OsKSL enzymes. (FIG. 2). Thus, 
it seems to be a novel kaurene synthase-like gene, Which has 
been designated OsKSLl l. The originally targeted sequence 
contained in AK108710 corresponds to OsKSL8, Which has 
recently been reported to encode a transcriptionally inducible 
syn-CPP speci?c stemarene synthase. Unfortunately, 
OsKSL8 and OsKSLll could not be distinguished by RT 
PCR analysis due to the extensive sequence similarity, despite 
repeated attempts With several primer combinations designed 
to discriminate betWeen the tWo. Therefore, it Was not pos 
sible to conclusively determine if transcription of OsKSLll 
is likeWise induced by UV-irradiation or application of the 
defensive signaling molecule methyl jasmonate. 
Functional characterization of OsKSLl l as a syn-CPP spe 
ci?c stemodene synthase. Full-length and truncated 
OsKSLll proteins Were expressed and puri?ed as fusions to 
GST. The recombinant protein Was then assayed With GGPP, 
ent-CPP, or syn-CPP as substrate, and enzymatic product 
formation assessed by GC-MS analysis of organic extracts. 
While the truncated construct exhibited better activity, both 
constructs Were catalytically active only With syn-CPP, and 
enzymatic products Were not observed With GGPP or ent 
CPP. Intriguingly, GC-MS analysis demonstrated that the 
major enzymatic product resulting from reactions With syn 
CPP did not correspond to authentic standards for any of the 
knoWn rice diterpenes. (FIG. 3). To produce su?icient quan 
tities of enzymatic product for NMR analysis, it Was chosen 
to use a coupled assay With puri?ed GST-tagged and trun 
cated versions of OsCPS4 (i.e., syn-CPP synthase) and 
OsKSLl l (i.e. because GGPP is much more readily available 
than syn-CPP). In this Way, it Was possible to produce ~l 50 pg 
of the unknoWn diterpene product. Comparison of the GC 
MS fragmentation pattern and NMR proton data With litera 
ture values initially suggested that OsKSLll Was producing 
aphidicol-l6-ene. HoWever, given the close phylogenetic 
relationship With syn-stemarene synthase (OsKSL8) and the 
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fact that OsKSLll also produces small amounts (~3%) of 
stemar-l3-ene (endo double bond), it is strongly suspected 
that this product Was actually the mechanistically related 
stemod-l3(l7)-ene). Synthetic (:)-stemodene, as a mixture 
of the exo (l3(l7)-ene) and endo (l2-ene) double bond iso 
mers, Was obtained as a kind gift from Dr. James White. The 
enzymatic products of OsKSLll With syn-CPP Were then 
shoWn to be ~92% exo-stemodene, ~5% endo-stemodene, 
and the aforementioned ~3% endo-stemarene, by GC analy 
ses, including GC-MS comparison to authentic samples (FIG. 
3). The identi?cation of the major product as exo-stemodene 
Was con?rmed by high ?eld proton NMR spectra of the enzy 
matic product mixture and comparisons With spectra and data 
of the (:)-exo-stemodene standard, for Which proton and 
carbon NMR assignments (Table 1) Were made With the aid of 
COSY, NOE, HMQC, and APT spectral analyses. 
TABLE 1 
500 MHZ 1H and 126 MHZ 13C NMR data 
and assignments 
for synthetic (:)—sternod—l3(l7)—ene in C6D‘ 
c# 66 6H m J(Hz) 
1 42.5 HOL 1.14 td 12.3, 3.2 
H[3 1.30-1.46 m 
2 37.2 HOL 1.52 brd 12.7 
H[3 1.43 qt 12.5, 3.0 
3 36.7 HOL 1.07 td 12.8, 3.3 
H[3 1.33 dt 131,36 
4 33.7 
5 47.8 1.17 d 12.7 
6 19.5 HOL 1.30-1.46 H1 
H8 1.11 qd 12.8, 3.3 
7 23.0 HOL 1.40 ddd 12.2, 7.4, 2.5 
H[3 1.74-1.81 m 
8 39.6 1.63-1.69 m 
9 51.7 
10 39.1 
11 32.7 HOL 1.42 dd 10.1,5.2 
H[3 1.40-1.42 m 
12 28.9 HOL 2.10 ddd 15.0, 4.4, 3.3 
H[3 2.23-2.31 m 
13 155.5 
14 44.3 2.73 t 6.7 
15 40.4 HOL 1.27 ddd 13.8, 6.1,2.6 
H[3 1.82 dd 13.5, 8.1 
16 38.2 HOL 1.97 ddd 11.2, 5.6, 1.7 
H[3 1.24 d 11.3 
17 102.8 HE 4.58 t 2.2 
Hz 4.67 t 2.4 
18 19.2 0.90 s 
19 23.3 0.89 s 
20 35.1 0.91 s 
5: chemical shift in ppm (C6H6 reference 7.16 ppm); 
In: apparent multiplicity; 
.I: apparent coupling constant 
For the above-stated reasons, it is submitted that the present 
invention accomplishes at least all of its stated objectives. 
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Having described the invention With reference to particular 
compositions and methods, theories of effectiveness, and the 
like, it Will be apparent to those of skill in the art that it is not 
intended that the invention be limited by such illustrative 
embodiments or mechanisms, and that modi?cations can be 
made Without departing from the scope or spirit of the inven 
tion, as de?ned by the appended claims. It is intended that all 
such obvious modi?cations and variations be included Within 
the scope of the present invention as de?ned in the appended 
claims. The claims are meant to cover the claimed compo 
nents and steps in any sequence Which is effective to meet the 
objectives there intended. 
All articles cited herein and in the following list are hereby 
expressly incorporated in their entirety by reference. 
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SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 812 
TYPE: PRT 
ORGANISM: Oryza sativa 
<400> SEQUENCE: 1 
Met Met Met Leu Leu 
1 5 
Ser Ser Ser 
10 
Leu Pro Ser Ser 
Cys Pro Gly Gly Gln Phe His Ala Pro Pro 
20 
Gly Arg 
Arg Arg Gly Val Thr Val Ile Glu 
35 
Arg Tyr 
40 
Lys Arg 
45 
Ala Leu Gln Met His 
55 
Gly Gly Asn Ser Ser 
50 
Asp Arg 
60 
Ala 
65 
Thr Gln Gln Thr Glu Arg Arg Asp Leu Leu Leu 
Cys 
Val 
Leu 
Lys 
Ser 
Cys 
Met 
Gly 
Glu 
Thr 
Cys 
15 
Arg 
Ala Pro 
Val Gly 
Gln Leu 
Leu 
80 
Ser 
19 
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Tyr 
Asp 
Asp 
Asn 
145 
Asn 
Glu 
Glu 
Ala 
225 
Asp 
Pro 
Leu 
Thr 
Leu 
305 
Ile 
Met 
Asn 
Ser 
Leu 
385 
Ser 
Ser 
Lys 
Lys 
465 
Ala 
Asp 
Pro 
Asp 
Val 
130 
Val 
Phe 
Ile 
Phe 
Ile 
210 
Tyr 
Glu 
Ser 
Gln 
Val 
290 
Glu 
Leu 
Leu 
Gly 
Ser 
370 
Ile 
Ile 
Val 
Tyr 
Lys 
450 
Thr 
Val 
Thr 
Cys 
Gly 
115 
Leu 
Gly 
Ser 
Thr 
Pro 
195 
Glu 
Met 
Ile 
Thr 
Tyr 
275 
Tyr 
Lys 
Asp 
Asp 
Tyr 
355 
Phe 
Glu 
Leu 
Cys 
Ala 
435 
Arg 
Glu 
Glu 
Ala 
Phe 
100 
Ser 
Ser 
Gln 
Ile 
Phe 
180 
Val 
Leu 
Ala 
Met 
Thr 
260 
Leu 
Pro 
Met 
Thr 
Ile 
340 
His 
Arg 
Leu 
Asp 
Ser 
420 
Leu 
Asn 
Tyr 
Asp 
Trp 
85 
Pro 
Trp 
Ser 
Glu 
Ala 
165 
Pro 
Arg 
Glu 
Tyr 
Met 
245 
Ala 
Asn 
Leu 
Gly 
Thr 
325 
Thr 
Val 
Glu 
Tyr 
Ser 
405 
Asn 
Lys 
Ile 
Leu 
Phe 
485 
Val 
Gln 
Gly 
Thr 
His 
150 
Met 
Gly 
Gln 
Arg 
Val 
230 
Phe 
Ala 
Cys 
Asn 
Ile 
310 
Tyr 
Thr 
Ser 
Ser 
Lys 
390 
Ile 
Gly 
Phe 
Glu 
Leu 
470 
Ser 
Ala 
Cys 
Thr 
Leu 
135 
Ile 
Asp 
Met 
Thr 
Glu 
215 
Thr 
Gln 
Thr 
Leu 
Ile 
295 
Ser 
Val 
Cys 
Ser 
Leu 
375 
Ala 
Gly 
Val 
Pro 
Arg 
455 
Pro 
Ser 
Met 
Val 
Arg 
120 
Ala 
Arg 
Glu 
Leu 
Asp 
200 
Ala 
Glu 
Arg 
Leu 
Val 
280 
Tyr 
Gln 
Ser 
Ala 
Val 
360 
Gln 
Ser 
Ser 
Lys 
Phe 
440 
Phe 
His 
Ser 
Val 
Glu 
105 
Gly 
Cys 
Arg 
Gln 
Ser 
185 
Val 
Gly 
Gly 
Lys 
Val 
265 
Ser 
Cys 
Tyr 
Trp 
Met 
345 
Glu 
Gly 
Lys 
Trp 
Lys 
425 
Tyr 
Asp 
Ala 
Gln 
Pro 
90 
Trp 
Phe 
Val 
Gly 
Ile 
Leu 
Asp 
Asp 
Leu 
Asn 
250 
Asn 
Lys 
Gln 
Phe 
Leu 
330 
Ala 
Leu 
Tyr 
Val 
Ser 
410 
Ala 
Thr 
Ala 
Asn 
Ser 
490 
Leu 
Ile 
Gly 
Leu 
Leu 
155 
Ala 
Ala 
Arg 
His 
Gly 
235 
Gly 
His 
Phe 
Leu 
Val 
315 
Glu 
Phe 
Ser 
Leu 
Ser 
395 
Gly 
Pro 
Thr 
Lys 
Ile 
Arg 
Leu 
Val 
Ala 
140 
Asp 
Ala 
Met 
Leu 
Ser 
220 
Asn 
Ser 
Tyr 
Gly 
Ser 
300 
Ser 
Arg 
Arg 
Pro 
Asn 
380 
Lys 
Ser 
Ile 
Leu 
Asp 
460 
Asp 
Tyr 
Gly 
Gln 
Ala 
125 
Leu 
Phe 
Pro 
Gly 
Leu 
205 
Tyr 
Leu 
Phe 
Asn 
Ser 
285 
Trp 
Glu 
Asp 
Leu 
Val 
365 
Asp 
Ser 
Leu 
Phe 
Asp 
445 
Ser 
Ile 
Gln 
Ser 
Asn 
110 
Val 
Lys 
Ile 
Val 
Met 
190 
His 
Gly 
Leu 
Phe 
Asp 
270 
Ala 
Val 
Ile 
Glu 
Leu 
350 
Ala 
Lys 
Glu 
Leu 
Glu 
430 
Arg 
Gln 
Leu 
Asp 
Arg 
95 
Gln 
Thr 
Arg 
Gly 
Gly 
Asp 
Leu 
Arg 
Glu 
Asn 
255 
Lys 
Val 
Asp 
Lys 
Glu 
335 
Arg 
Glu 
Lys 
Asn 
Lys 
415 
Glu 
Leu 
Met 
Ala 
Glu 
495 
Gln 
Gln 
Arg 
Trp 
Arg 
160 
Phe 
Leu 
Arg 
Lys 
Trp 
240 
Cys 
Ala 
Pro 
Ala 
Ser 
320 
Ile 
Met 
Ala 
Ser 
Glu 
400 
Glu 
Met 
Asp 
Leu 
Leu 
480 
Leu 
21 
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Phe 
Ile 
Gly 
545 
Lys 
Ile 
Gly 
Arg 
625 
Thr 
Pro 
Asp 
Thr 
Leu 
705 
Gly 
Asp 
Ala 
Val 
Met 
785 
Val 
Tyr 
Ala 
Phe 
530 
Val 
Glu 
Gln 
Tyr 
Arg 
610 
Ser 
Met 
Ile 
Val 
Cys 
690 
Glu 
Ser 
Thr 
Val 
His 
770 
Val 
Ser 
Leu 
Arg 
515 
Pro 
Leu 
Glu 
Glu 
Thr 
595 
Asp 
Met 
Glu 
Val 
Val 
675 
Gly 
Gly 
Ile 
Ser 
Pro 
755 
Met 
Ser 
Asp 
Glu 
500 
Gln 
Arg 
Thr 
Leu 
Glu 
580 
Thr 
Val 
Met 
Glu 
Leu 
660 
Arg 
Arg 
Lys 
Ser 
Arg 
740 
Arg 
Phe 
Ala 
Pro 
Cys 
Lys 
Glu 
Thr 
Glu 
565 
Phe 
Val 
Thr 
Thr 
Tyr 
645 
Pro 
Asp 
Leu 
Leu 
Ile 
725 
Arg 
Pro 
Tyr 
Val 
Tyr 
805 
<2l2> TYPE: 
<2l3> ORGANISM: Oryza sativa 
PRT 
<400 > SEQUENCE: 
837 
2 
Trp 
Leu 
Leu 
Val 
550 
Asn 
Tyr 
Asn 
Lys 
Glu 
630 
Met 
Thr 
His 
Leu 
Asn 
710 
Asp 
Asn 
Cys 
Ser 
Asn 
790 
Gly 
Met Met Leu Leu Gly Ser 
1 5 
Ala Gly Ala Ser Pro 
20 
Lys Gln Pro Ser Ser 
35 
Asn Asp Leu Arg Ile 
50 
Ala 
Arg 
Leu 
Val 
Thr 
Ser 
535 
Val 
Leu 
Ser 
Gln 
His 
615 
Ala 
Ala 
Leu 
Glu 
Asn 
695 
Ser 
Glu 
Leu 
Lys 
Arg 
775 
Ala 
Ser 
Pro 
Gly 
Ala 
Ser 
55 
Lys 
Tyr 
520 
Glu 
Asp 
Ile 
Glu 
Leu 
600 
Leu 
Glu 
Asn 
Tyr 
Tyr 
680 
Asp 
Val 
Ala 
Leu 
760 
Thr 
Val 
Ile 
Ser 
Gly 
Pro 
40 
Pro 
Asp 
505 
Cys 
Ala 
Asp 
Ala 
585 
Gly 
Thr 
Trp 
Ala 
Phe 
665 
Asn 
Ser 
Ser 
Lys 
Arg 
745 
Leu 
Asp 
Val 
Leu 
Ser 
Thr 
25 
Pro 
Ala 
Glu 
Tyr 
Arg 
Phe 
Leu 
570 
Val 
Ala 
Glu 
Gln 
Val 
650 
Val 
Glu 
Gln 
Leu 
Met 
730 
Leu 
Phe 
Gly 
Lys 
Ser 
810 
Gly 
Thr 
Pro 
Ala 
Lys 
Leu 
Ile 
Phe 
555 
Val 
Arg 
Lys 
Ile 
Arg 
635 
Val 
Gly 
Leu 
Gly 
Leu 
715 
Lys 
Val 
Trp 
Phe 
Glu 
795 
Gly 
Gly 
Thr 
Gly 
Ala 
Leu Asp Gln Leu 
Ser 
Ala 
540 
Asp 
Glu 
Ile 
Ala 
Trp 
620 
Thr 
Ser 
Pro 
Phe 
Phe 
700 
Val 
Ala 
Leu 
Lys 
Ser 
780 
Pro 
Asn 
Tyr 
Met 
Ile 
Ala 
60 
Ala 
525 
Trp 
Leu 
Lys 
Val 
Ser 
605 
Leu 
Lys 
Phe 
Lys 
Arg 
685 
Glu 
His 
Gln 
Gly 
Met 
765 
Ser 
Leu 
Gly 
Ala 
Thr 
45 
Ala 
510 
Ala 
Ala 
Gly 
Trp 
Phe 
590 
Ala 
Cys 
Tyr 
Ala 
Leu 
670 
Leu 
Arg 
His 
Lys 
Glu 
750 
Cys 
Pro 
Lys 
Gly 
Pro 
30 
Gly 
Ala 
Ala 
Lys 
Gly 
Asp 
575 
Ser 
Leu 
Leu 
Val 
Leu 
655 
Gln 
Met 
Glu 
Ser 
Ser 
735 
Gln 
Lys 
Lys 
Leu 
Lys 
15 
Ser 
Gly 
Val 
Pro 
Thr 
Asn 
Ser 
560 
Gly 
Ala 
Gln 
Met 
Pro 
640 
Gly 
Glu 
Ser 
Ser 
Gly 
720 
Ile 
Gly 
Ile 
Glu 
Lys 
800 
Phe 
Ala 
Arg 
Gly 
23 
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Gly 
65 
Gln 
Gln 
Met 
Val 
Arg 
145 
Ala 
Arg 
Glu 
Leu 
Asp 
225 
Ala 
Glu 
Arg 
Leu 
Val 
305 
Tyr 
Gln 
Ser 
Ala 
Val 
385 
Gln 
Ser 
Ser 
Lys 
Phe 
465 
Leu 
Ala 
Thr 
Val 
Glu 
130 
Gly 
Cys 
Arg 
Gln 
Ser 
210 
Val 
Gly 
Gly 
Lys 
Val 
290 
Ser 
Cys 
Tyr 
Trp 
Met 
Glu 
Gly 
Lys 
Trp 
Lys 
450 
Tyr 
Glu 
Thr 
Leu 
Pro 
115 
Trp 
Phe 
Val 
Gly 
Ile 
195 
Leu 
Asp 
Asp 
Leu 
Asn 
275 
Asn 
Lys 
Gln 
Phe 
Leu 
355 
Ala 
Leu 
Tyr 
Val 
Ser 
435 
Ala 
Thr 
Met 
His 
Glu 
100 
Leu 
Ile 
Gly 
Leu 
Leu 
180 
Ala 
Ala 
Arg 
His 
Gly 
260 
Gly 
His 
Phe 
Leu 
Val 
340 
Glu 
Phe 
Ser 
Leu 
Ser 
420 
Gly 
Pro 
Thr 
Lys 
Arg 
Leu 
Arg 
Leu 
Val 
Ala 
165 
Asp 
Ala 
Met 
Leu 
Ser 
245 
Asn 
Ser 
Tyr 
Gly 
Ser 
325 
Ser 
Arg 
Arg 
Pro 
Asn 
405 
Lys 
Ser 
Ile 
Leu 
Lys 
Lys 
Ser 
Gly 
Gln 
Ala 
150 
Leu 
Phe 
Pro 
Gly 
Leu 
230 
Tyr 
Leu 
Phe 
Asn 
Ser 
310 
Trp 
Glu 
Asp 
Leu 
Val 
390 
Asp 
Ser 
Leu 
Phe 
Asp 
470 
Pro 
Glu 
Thr 
Ser 
Asn 
135 
Val 
Lys 
Ile 
Val 
Met 
215 
His 
Gly 
Leu 
Phe 
Asp 
295 
Ala 
Val 
Ile 
Glu 
Leu 
375 
Ala 
Lys 
Glu 
Leu 
Glu 
455 
Arg 
Glu 
Leu 
Ser 
Arg 
120 
Gln 
Thr 
Arg 
Gly 
Gly 
200 
Asp 
Leu 
Arg 
Glu 
Asn 
280 
Lys 
Val 
Asp 
Lys 
Glu 
360 
Arg 
Glu 
Lys 
Asn 
Lys 
440 
Glu 
Leu 
Ala 
Glu 
Leu 
105 
Gln 
Gln 
Arg 
Trp 
Arg 
185 
Phe 
Leu 
Arg 
Lys 
Trp 
265 
Cys 
Ala 
Pro 
Ala 
Ser 
345 
Ile 
Met 
Ala 
Ser 
Glu 
425 
Glu 
Met 
Asp 
Glu 
Ala 
Tyr 
His 
Asp 
Asp 
Asn 
170 
Asn 
Asn 
Glu 
Glu 
Ala 
250 
Asp 
Pro 
Leu 
Thr 
Leu 
330 
Ile 
Met 
Asn 
Ser 
Leu 
410 
Ser 
Ser 
Lys 
His 
Gly 
Ser 
Asp 
Pro 
Asp 
Val 
155 
Val 
Phe 
Ile 
Phe 
Ile 
235 
Tyr 
Glu 
Ser 
Gln 
Val 
315 
Glu 
Leu 
Leu 
Gly 
Ser 
395 
Ile 
Ile 
Val 
Tyr 
Lys 
475 
Ile 
Ile 
Thr 
Cys 
Gly 
140 
Leu 
Gly 
Ser 
Thr 
Pro 
220 
Glu 
Met 
Ile 
Thr 
Tyr 
300 
Tyr 
Lys 
Asp 
Asp 
Tyr 
380 
Phe 
Glu 
Leu 
Cys 
Ala 
460 
Arg 
Ala 
Arg 
Ala 
Phe 
125 
Ser 
Ser 
Gln 
Ile 
Phe 
205 
Val 
Leu 
Ala 
Met 
Thr 
285 
Leu 
Pro 
Met 
Thr 
Ile 
365 
His 
Arg 
Leu 
Asp 
Ser 
445 
Leu 
Asn 
Glu 
Lys 
Trp 
110 
Pro 
Trp 
Ser 
Glu 
Ala 
190 
Pro 
Arg 
Glu 
Tyr 
Met 
270 
Ala 
Asn 
Leu 
Gly 
Thr 
350 
Thr 
Val 
Glu 
Tyr 
Ser 
430 
Asn 
Lys 
Ile 
Ser 
Gln 
95 
Val 
Gln 
Gly 
Thr 
His 
175 
Met 
Gly 
Gln 
Arg 
Val 
255 
Phe 
Ala 
Cys 
Asn 
Ile 
335 
Tyr 
Thr 
Ser 
Ser 
Lys 
415 
Ile 
Gly 
Phe 
Glu 
Leu 
80 
Leu 
Ala 
Cys 
Thr 
Leu 
160 
Ile 
Asp 
Met 
Thr 
Glu 
240 
Thr 
Gln 
Thr 
Leu 
Ile 
320 
Ser 
Val 
Cys 
Ser 
Leu 
400 
Ala 
Gly 
Val 
Pro 
Arg 
480 
25 
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26 
Phe 
Ser 
Lys 
Tyr 
545 
Glu 
Asp 
Ile 
Glu 
Leu 
625 
Leu 
Glu 
Asn 
Tyr 
Tyr 
705 
Asp 
Val 
Ala 
Leu 
785 
Thr 
Val 
Ile 
Asp 
Ala 
Gln 
Asp 
530 
Cys 
Ala 
Asp 
Ala 
610 
Gly 
Thr 
Trp 
Ala 
Phe 
690 
Asn 
Ser 
Ser 
Lys 
Arg 
770 
Leu 
Asp 
Val 
Leu 
Ala 
Asn 
Ser 
515 
Glu 
Tyr 
Arg 
Phe 
Leu 
595 
Val 
Ala 
Glu 
Gln 
Val 
675 
Val 
Glu 
Gln 
Leu 
Met 
755 
Leu 
Phe 
Gly 
Lys 
Ser 
835 
Lys 
500 
Ile 
Lys 
Leu 
Ile 
Phe 
580 
Val 
Arg 
Lys 
Ile 
Arg 
660 
Val 
Gly 
Leu 
Gly 
Leu 
740 
Lys 
Val 
Trp 
Phe 
Glu 
820 
Gly 
Asp 
485 
Asp 
Tyr 
Leu 
Ser 
Ala 
565 
Asp 
Glu 
Ile 
Ala 
Trp 
645 
Thr 
Ser 
Pro 
Phe 
Phe 
725 
Val 
Ala 
Leu 
Lys 
Ser 
805 
Pro 
Asn 
<2l2> TYPE: 
<2l3> ORGANISM: Oryza sativa 
PRT 
<400 > SEQUENCE: 
836 
3 
Ser 
Ile 
Gln 
Asp 
Ala 
550 
Trp 
Leu 
Lys 
Val 
Ser 
630 
Leu 
Lys 
Phe 
Lys 
Arg 
710 
Glu 
His 
Gln 
Gly 
Met 
790 
Ser 
Leu 
Gln 
Leu 
Asp 
535 
Ala 
Ala 
Gly 
Trp 
Phe 
615 
Ala 
Cys 
Tyr 
Ala 
Leu 
695 
Leu 
Arg 
His 
Lys 
Glu 
775 
Cys 
Pro 
Lys 
Met 
Ala 
Glu 
520 
Leu 
Ala 
Lys 
Gly 
Asp 
600 
Ser 
Leu 
Leu 
Val 
Leu 
680 
Gln 
Met 
Glu 
Ser 
Ser 
760 
Gln 
Lys 
Lys 
Leu 
Leu 
Leu 
505 
Leu 
Pro 
Thr 
Asn 
Ser 
585 
Gly 
Ala 
Gln 
Met 
Pro 
665 
Gly 
Glu 
Ser 
Ser 
Gly 
745 
Ile 
Gly 
Ile 
Glu 
Lys 
825 
Lys 
490 
Ala 
Asn 
Phe 
Ile 
Gly 
570 
Lys 
His 
Ile 
Gly 
Arg 
650 
Thr 
Pro 
Asp 
Thr 
Leu 
730 
Gly 
Asp 
Ala 
Val 
Met 
Val 
Thr 
Val 
Tyr 
Ala 
Phe 
555 
Val 
Glu 
Gln 
Tyr 
Arg 
635 
Ser 
Met 
Ile 
Val 
Cys 
Glu 
Ser 
Thr 
Val 
His 
795 
Val 
Ser 
Glu 
Glu 
Leu 
Arg 
540 
Pro 
Leu 
Glu 
Glu 
Thr 
620 
Asp 
Met 
Glu 
Val 
Val 
700 
Gly 
Gly 
Ile 
Ser 
Pro 
780 
Met 
Ser 
Asp 
Tyr 
Asp 
Glu 
525 
Gln 
Arg 
Thr 
Leu 
Glu 
605 
Thr 
Val 
Met 
Glu 
Leu 
685 
Arg 
Arg 
Lys 
Ser 
Arg 
765 
Arg 
Phe 
Ala 
Pro 
Leu 
Phe 
Cys 
Lys 
Glu 
Thr 
Glu 
590 
Phe 
Val 
Thr 
Thr 
Tyr 
670 
Pro 
Asp 
Leu 
Leu 
Ile 
750 
Arg 
Pro 
Tyr 
Val 
Tyr 
830 
Leu 
495 
Ser 
Trp 
Leu 
Leu 
Val 
575 
Asn 
Tyr 
Asn 
Lys 
Glu 
655 
Met 
Thr 
His 
Leu 
Asn 
735 
Asp 
Asn 
Cys 
Ser 
Asn 
815 
Gly 
Pro 
Ser 
Val 
Thr 
Ser 
560 
Val 
Leu 
Ser 
Gln 
His 
640 
Ala 
Ala 
Leu 
Glu 
Asn 
720 
Ser 
Glu 
Leu 
Lys 
Arg 
800 
Ala 
Ser 
Met Glu Ala Val Ala Arg Ser Ser Leu Val Leu Ala Pro Arg Arg Arg 
1 5 
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28 
Arg 
Cys 
Ala 
Gly 
65 
Met 
Ile 
Ile 
Ala 
Ser 
145 
Asp 
Asn 
Asn 
Glu 
225 
Asp 
Ala 
Trp 
Ser 
Ala 
305 
Pro 
Thr 
Arg 
Val 
Met 
385 
Ala 
Ser 
Ala 
Arg 
Cys 
50 
Thr 
Val 
Arg 
Ala 
Pro 
130 
Asn 
Ile 
Val 
Phe 
Leu 
210 
Phe 
Met 
Tyr 
Ser 
Pro 
290 
Leu 
Thr 
Leu 
Ile 
Met 
Asn 
Ser 
Leu 
Leu 
Arg 
Ser 
Arg 
Gly 
Arg 
Trp 
115 
Cys 
Gly 
Leu 
Gly 
Ser 
195 
Thr 
Pro 
Glu 
Phe 
Glu 
275 
Ala 
Gly 
Val 
Val 
Leu 
355 
Leu 
Gly 
Thr 
Leu 
Gly 
20 
Arg 
Ala 
Ala 
Glu 
His 
100 
Val 
Phe 
Ser 
Leu 
Ser 
180 
Ile 
Phe 
Ala 
Leu 
Ala 
260 
Val 
Ala 
Tyr 
Tyr 
Asn 
340 
Asp 
Asp 
Tyr 
Phe 
Glu 
420 
Leu 
His 
Glu 
Val 
Asn 
85 
Leu 
Ala 
Pro 
Trp 
Ser 
165 
Glu 
Val 
Pro 
Ser 
Lys 
245 
Tyr 
Met 
Thr 
Leu 
Pro 
325 
Ile 
Lys 
Leu 
Gly 
His 
405 
Leu 
Leu 
Asn 
Leu 
Met 
Thr 
Glu 
Met 
Glu 
Gly 
150 
Thr 
Gln 
Ile 
Ala 
Glu 
230 
Arg 
Ile 
Lys 
Ala 
Tyr 
310 
Leu 
Gly 
Thr 
Pro 
Val 
390 
Asn 
Tyr 
Pro 
Gly 
Asp 
55 
Ser 
Ser 
Asn 
Val 
Cys 
135 
Val 
Leu 
Ile 
Asp 
Met 
215 
Ile 
Leu 
Ala 
Phe 
Ala 
295 
Ser 
Asn 
Ile 
Tyr 
Thr 
375 
Ser 
Ser 
Lys 
Ala 
Gly 
Thr 
Ser 
Gln 
Pro 
Pro 
120 
Val 
Asn 
Ala 
Arg 
Asp 
200 
Val 
Ser 
Ser 
Glu 
280 
Ala 
Val 
Ile 
Ser 
Ile 
360 
Cys 
Ser 
Val 
Ala 
Ala 
25 
Met 
Gly 
Cys 
Ile 
Glu 
105 
Leu 
Glu 
Glu 
Cys 
Arg 
185 
Gln 
Asn 
Ile 
Gly 
Gly 
265 
Gly 
Leu 
Val 
Phe 
Arg 
345 
Leu 
Ala 
Asp 
Glu 
Ser 
425 
Ala 
Arg 
Arg 
Pro 
Asn 
90 
Phe 
Pro 
Trp 
Phe 
Ile 
Gly 
Ile 
Leu 
Asp 
Glu 
250 
Leu 
Lys 
Val 
Asn 
Ser 
330 
His 
Trp 
Met 
Asp 
Gly 
410 
Lys 
Ala 
Arg 
Arg 
Gly 
Met 
Leu 
Gly 
Ile 
Asp 
155 
Ile 
Leu 
Ala 
Ala 
235 
Glu 
Glu 
Asn 
His 
Lys 
315 
Gln 
Phe 
Ser 
Ala 
Leu 
395 
Tyr 
Val 
Pro 
Pro 
Gln 
60 
Tyr 
Gly 
Pro 
Thr 
Leu 
140 
Ser 
Ala 
His 
Ala 
Ile 
220 
Ile 
Ser 
Glu 
Gly 
Arg 
300 
Phe 
Leu 
Ser 
Gln 
Phe 
380 
Ser 
Leu 
Ser 
Phe 
His 
Leu 
Val 
Arg 
Ser 
Asp 
125 
Gln 
Ser 
Leu 
Phe 
Pro 
205 
Lys 
Leu 
Leu 
Ser 
Ser 
285 
Tyr 
Gly 
Ser 
Ser 
Arg 
365 
Arg 
His 
Asp 
Leu 
Val 
30 
Val 
Pro 
Glu 
Glu 
Ser 
110 
His 
Asn 
Ala 
Glu 
Ile 
190 
Ile 
Met 
His 
Gly 
Met 
Leu 
Asp 
Gly 
Met 
Asp 
350 
Asp 
Leu 
Val 
Asp 
Ser 
430 
Leu 
Ser 
Ser 
Gly 
Ala 
95 
Tyr 
Leu 
Gln 
Ser 
Lys 
175 
Ala 
Gly 
Gly 
Leu 
Lys 
255 
Val 
Phe 
Asp 
Glu 
Val 
335 
Ile 
Glu 
Leu 
Ala 
Thr 
415 
Glu 
Asp 
Phe 
Thr 
Arg 
80 
Arg 
Asp 
Gln 
His 
Lys 
160 
Trp 
Lys 
Phe 
Leu 
Arg 
240 
Glu 
Asp 
Asn 
Lys 
Val 
320 
Asp 
Lys 
Glu 
Arg 
Glu 
400 
Lys 
Asn 
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30 
Glu 
Glu 
Val 
465 
Asp 
Ile 
Leu 
Ile 
Glu 
545 
Thr 
Ser 
Ser 
Gln 
Phe 
625 
Val 
Tyr 
Val 
Leu 
Trp 
705 
Met 
Glu 
Ser 
Ser 
Asp 
785 
Lys 
Lys 
Thr 
Pro 
Lys 
450 
Glu 
His 
Lys 
Ala 
530 
Phe 
Ile 
Ile 
Lys 
Tyr 
610 
Ala 
Gln 
Leu 
Pro 
Gly 
690 
Glu 
Asn 
Cys 
Lys 
Ile 
770 
Gly 
Thr 
Glu 
Arg 
Ile 
435 
Leu 
Tyr 
Lys 
Thr 
Ala 
515 
His 
Thr 
Ser 
Ala 
Glu 
595 
His 
Leu 
Asn 
Arg 
Thr 
675 
Pro 
Asp 
Thr 
Lys 
Asp 
755 
Ser 
Val 
Ser 
Met 
Gly 
835 
Leu 
Cys 
Ala 
Trp 
Lys 
500 
Glu 
Leu 
Arg 
Pro 
Leu 
580 
Glu 
Lys 
Tyr 
Arg 
Ser 
660 
Met 
Thr 
Ile 
Cys 
Asp 
740 
Val 
Ser 
Ile 
His 
Met 
820 
Asn 
Glu 
Ser 
Leu 
Asn 
485 
Asn 
Asp 
Glu 
Lys 
Tyr 
565 
Thr 
Gln 
Val 
Ser 
Asp 
645 
Leu 
Glu 
Ile 
Val 
Gly 
725 
Gly 
Met 
Cys 
Pro 
Val 
805 
Gly 
Lys 
Asp 
Lys 
470 
Ile 
Met 
Phe 
Ser 
Asn 
550 
Glu 
Leu 
Glu 
Glu 
Thr 
630 
Val 
Ala 
Glu 
Leu 
Lys 
710 
Arg 
Lys 
Ser 
Arg 
Lys 
790 
Phe 
Ala 
Met 
Asp 
455 
Phe 
Glu 
Pro 
Ser 
Trp 
535 
Leu 
Leu 
Val 
Asn 
Phe 
Val 
Thr 
Thr 
Tyr 
Ile 
695 
Asn 
Leu 
Leu 
Val 
Arg 
775 
Ser 
Tyr 
Met 
Gly 
440 
Ile 
Pro 
Asn 
Cys 
Phe 
520 
Glu 
Ile 
Ser 
Ala 
Leu 
600 
Tyr 
Asn 
Lys 
Asp 
Met 
680 
Ala 
Ala 
Gln 
Asn 
Glu 
760 
Glu 
Cys 
Ser 
Asn 
Cys 
Arg 
Phe 
Phe 
His 
505 
Cys 
Lys 
Asn 
Asp 
Asp 
585 
Ile 
Ser 
Gln 
Tyr 
Ala 
665 
Lys 
Leu 
Glu 
Asn 
Ser 
745 
Glu 
Leu 
Lys 
Gln 
Gly 
825 
Trp 
Gly 
Tyr 
Asp 
490 
Val 
Gln 
Glu 
Ser 
Ala 
570 
Asp 
Ser 
Glu 
Leu 
Asn 
650 
Glu 
Asn 
Tyr 
Tyr 
Asp 
730 
Val 
Ala 
Leu 
Glu 
Ala 
Val 
Ser 
Thr 
Ala 
475 
Ala 
Asn 
Ser 
Asn 
Tyr 
555 
Arg 
Phe 
Leu 
Asn 
Gly 
635 
Val 
Trp 
Ser 
Phe 
Asp 
715 
Ile 
Ser 
Lys 
Arg 
Met 
795 
Asp 
Ile 
Gly 
Pro 
460 
Thr 
Arg 
Glu 
Thr 
Lys 
540 
Leu 
Ile 
Phe 
Val 
Val 
620 
Ala 
Glu 
Gln 
Ile 
Met 
700 
Glu 
Gln 
Leu 
Glu 
Leu 
780 
Phe 
Gly 
Phe 
Ser 
445 
Ile 
Leu 
Ala 
Asp 
Tyr 
525 
Leu 
Ser 
Ala 
Asp 
Glu 
605 
Lys 
Met 
Ser 
Arg 
Val 
685 
Gly 
Leu 
Ser 
Leu 
Ala 
765 
Val 
Trp 
Phe 
Glu 
Leu 
Leu 
Glu 
Tyr 
Leu 
510 
Gln 
Asp 
Ala 
Cys 
Val 
590 
Lys 
Ala 
Ala 
Trp 
Ser 
670 
Thr 
Gln 
Phe 
Phe 
Val 
750 
Ile 
Val 
Asn 
Ser 
Pro 
830 
Leu 
Gly 
Pro 
Gln 
495 
Leu 
Asn 
Gln 
Ala 
Ala 
575 
Gly 
Trp 
Val 
Ser 
Leu 
655 
Lys 
Phe 
Asn 
Arg 
Glu 
735 
Leu 
Asn 
Arg 
Leu 
Ser 
815 
Leu 
Lys 
Glu 
Leu 
480 
Lys 
Ala 
Glu 
Leu 
Ala 
560 
Lys 
Ser 
Asp 
Phe 
Ala 
640 
Asp 
Tyr 
Ala 
Leu 
Leu 
720 
Arg 
Asp 
Glu 
Glu 
Tyr 
800 
Pro 
Lys 











